Systematic review: interferon‐free regimens for patients with HCV‐related Child C cirrhosis

Guarino, Maria; Morisco, Filomena; Valvano, Maria Rosa; Ippolito, A.; Librandi, Marta; Andriulli, Nicola; Greco, Mónica; Amoruso, A.; Iacobellis, A.; Niro, G.A.; Caporaso, N.; Andriulli, Angelo

doi:10.1111/apt.14017

Cited by 22 publications

(28 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The only variable that remained significant on multivariable analysis was the MELD score. A MELD of 20 or more was highly predictive of transplantation, the odds ratio for MELD ≥ 20 being 13 Child-Pugh scores compared to our cohort. In the SOLAR 1 and SOLAR 2 studies of sofosbuvir and ledipasvir with and without ribavirin, over 50% of patients were Child-Pugh B and in the Ally-1 study only 26% were Child-Pugh C, whilst 53% were Child-Pugh B.…”

Section: Deaths and Transplantationcontrasting

confidence: 42%

See 1 more Smart Citation

Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15)

McCaughan

Thwaites

Roberts

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Deaths and Transplantationcontrasting

confidence: 42%

“…There was no significant change in Child-Pugh score or ALT (Table 7). .0001 16 (15.5-18) 12.5 (11)(12)(13)(14)(15)(16)(17) .065…”

Section: Deaths and Transplantationmentioning

confidence: 99%

Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15)

McCaughan

Thwaites

Roberts

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…While patients with cirrhosis are often not eligible to undergo IFN-based treatment, direct-acting antivirals (DAAs) including NS5B and NS5A inhibitors are safe and effective for patients with advanced liver disease, including those with decompensated cirrhosis [14]. The high SVR rates leading to stabilization and improvement of liver function raise hope that treatment with DAAs can reduce the rate of HCC among patients with former chronic HCV infection.…”

Section: Introductionmentioning

confidence: 99%

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals

et al. 2018

View full text Add to dashboard Cite

Background and Aims: The aim of the study was to evaluate the risk of hepatocellular carcinoma (HCC) development after treatment with direct-acting antivirals (DAAs) and to compare HCC occurrence in these patients with that among patients treated with interferon (IFN)-based therapies. Methods: We analyzed a large cohort with chronic hepatitis C virus patients for the onset of new HCC after DAA treatment. A historical IFN-treated cohort was investigated for comparison. Results: A total of 819 patients were included in the DAA group. The median follow-up period was 263 days (0–1,001). Twenty-five patients (3.6 HCCs/100 person-years; 3.1%) were diagnosed with de novo HCC within the time of observation. No patient without cirrhosis had developed HCC. Patients with newly diagnosed HCC were mostly male, older, and treatment-experienced and had a lower 12-week sustained virologic response (SVR12) rate and higher levels of liver inflammation markers. The median time to HCC was 312 days (0–880). Investigation of the subcohort of 269 cirrhotic patients yielded an HCC rate of 8.9 HCCs/100 person-years. In this cohort, non-SVR12 was an independent risk factor for de novo HCC (HR 4.48; 95% CI 1.51–13.12; p = 0.007). Twenty-four patients (96%) with new HCC were Child-Pugh class A and 17 (68%) were diagnosed in early BCLC stage A. For the IFN-treated patients, we calculated an overall risk of HCC occurrence of 1.3/100 person-years (19 patients out of 351; 5.4%). The median time to diagnosis was 38.8 months (0–113). Conclusion: The de novo HCC rates did not differ between the DAA-treated patients and those who received IFN. Achievement of SVR is of utmost importance for HCC prevention.

show abstract

“…1 should be urgently evaluated in Child C cirrhosis. However, protease inhibitors should not be used in Child B cirrhosis and they are also contraindicated in Child C cirrhosis.…”

Section: Sirsmentioning

confidence: 99%

Letter: the efficacy of interferon‐free regimens in HCV‐related Child C cirrhosis needs careful interpretation

Rezaee‐Zavareh

Alavian

2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Systematic review: interferon‐free regimens for patients with HCV‐related Child C cirrhosis

Abstract: The improvement in MELD scores strongly suggests HCV-positive patients with Child C cirrhosis should be treated with these agents.

Cited by 22 publications

References 32 publications

Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15)

Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15)

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals

Letter: the efficacy of interferon‐free regimens in HCV‐related Child C cirrhosis needs careful interpretation

Contact Info

Product

Resources

About